MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX) will host a virtual investor webcast and conference call at 8:00 am ET on June 12, 2026 to discuss once-weekly canvuparatide presentations at ENDO 2026 in Chicago.

The event will cover Phase 2 Avail 12-week results and one-year open-label extension data.

News Market Reaction – MBX

-2.61%

-2.61% Session close to close

In the Jun 1 session, MBX declined 2.61%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines a concentrated catalyst window at ENDO 2026, with one-year open-label Pha...

Analysis

This announcement outlines a concentrated catalyst window at ENDO 2026, with one-year open-label Phase 2 data and full 12-week Avail Phase 2 results for once-weekly canvuparatide. It follows recent earnings and obesity portfolio updates that emphasized a sizeable cash balance of $440.0M and plans for Phase 3 initiation in Q3 2026. Investors may watch the depth of efficacy and safety data, management commentary, and any subsequent capital-raising activity under the existing S-3ASR program.

Key Figures

Investor call time: 8:00 am ET ENDO OLE date: June 12, 2026 ENDO oral presentation: 3:00 pm CT +5 more

8 metrics

Investor call time 8:00 am ET Conference call and webcast on June 12, 2026

ENDO OLE date June 12, 2026 One-year OLE Phase 2 canvuparatide data at 3rd Parathyroid Summit

ENDO oral presentation 3:00 pm CT Oral presentation of 12-week Avail Phase 2 results on June 13, 2026

U.S. dial-in 1-877-407-0779 Domestic participant phone number for MBX investor call

International dial-in 1-201-389-0914 International participant phone number for MBX investor call

ATM capacity $250,000,000 Common stock under sales agreement prospectus supplement in S-3ASR

Current price $31.47 Pre-news trading level vs ENDO 2026 investor event announcement

52-week range $9.43–$45.85 MBX 52-week low and high before ENDO 2026 news

Historical Context

5 past events · Latest: May 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 26	Conference appearance	Neutral	-0.3%	Jefferies 2026 Global Healthcare Conference presentation and webcast disclosure.
May 11	Clinical data update	Positive	-2.2%	Initial Phase 1 MBX 4291 obesity data and obesity pipeline expansion details.
May 7	Earnings and pipeline	Positive	+8.1%	Q1 2026 results, cash position, and Phase 2/3 canvuparatide and obesity milestones.
May 7	Management change	Positive	+8.1%	Appointment of a Chief Commercial Officer and associated inducement equity grant.
Apr 23	Investor event	Neutral	-0.6%	Announcement of Obesity Day to discuss obesity portfolio and PEP platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent MBX news has mostly aligned with price reactions, with positive clinical and earnings updates seeing gains, while one obesity data update sold off despite favorable information.

Recent Company History

Over the last few months, MBX has highlighted multiple catalysts across its precision peptide pipeline. A Q1 2026 update reported $440.0M in cash and plans to start Phase 3 for once-weekly canvuparatide in Q3 2026, with shares rising about 8%. Obesity portfolio updates on May 11, 2026 with initial MBX 4291 data saw a modest decline. Investor-focused events, including Obesity Day on May 11 and a Jefferies conference appearance on June 3, 2026, had relatively small price moves. Today’s ENDO-focused investor event continues this pattern of data-centric communication.

Key Terms

open-label extension, phase 2, endocrinologist, webcast

4 terms

open-label extension medical

"One-year open-label extension (OLE) data from the Phase 2 trial..."

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

phase 2 medical

"One-year open-label extension (OLE) data from the Phase 2 trial..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

endocrinologist medical

"Michael T. Collins, M.D., endocrinologist and Senior Clinical Advisor..."

A medical specialist who diagnoses and treats conditions caused by hormones and the glands that produce them, such as diabetes, thyroid disorders, and reproductive hormone imbalances. For investors, endocrinologists influence how new drugs, devices, or diagnostic tests are used in practice, help design and interpret clinical trials, and shape prescribing patterns—think of them as the specialist mechanics who determine whether a hormone-related treatment will work and be adopted widely.

webcast technical

"will host an investor webcast and conference call at 8:00 am ET..."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026) in Chicago.

One-year open-label extension (OLE) data from the Phase 2 trial of once-weekly canvuparatide will be presented at the 3^rd Parathyroid Summit during ENDO 2026 on Friday, June 12, 2026. Full results from the 12-week Avail^TM Phase 2 trial of once-weekly canvuparatide will be presented in an oral presentation at ENDO 2026 at 3:00 pm CT on Saturday, June 13, 2026.

The Company will host a conference call and webcast at 8:00 am ET on Friday, June 12, 2026 to discuss full results from the 12-week Avail^TM Phase 2 trial and one-year OLE data for once-weekly canvuparatide. Company management will be joined by Richard DiMarchi, Ph.D., Distinguished Professor of Chemistry at Indiana University and MBX scientific co-founder, and Michael T. Collins, M.D., endocrinologist and Senior Clinical Advisor at the National Institutes of Health. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at https://investors.mbxbio.com/news-events/events.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
(937) 232-4889

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When is the MBX (Nasdaq: MBX) investor webcast about canvuparatide in June 2026?

The investor webcast is scheduled for 8:00 am ET on Friday, June 12, 2026. According to MBX Biosciences, the call will review 12-week Phase 2 Avail trial results and one-year open-label extension data for once-weekly canvuparatide.

What will MBX discuss about once-weekly canvuparatide at ENDO 2026?

MBX plans to discuss once-weekly canvuparatide Phase 2 Avail 12-week results and one-year open-label extension data. According to MBX, these data will be featured at the Endocrine Society’s ENDO 2026 meeting and the 3rd Parathyroid Summit in Chicago.

How can investors join the MBX Biosciences (MBX) canvuparatide investor call on June 12, 2026?

Investors can join via live webcast or by dialing 1-877-407-0779 (US) or 1-201-389-0914 (international). According to MBX, a live and archived webcast plus slides will be available in the Investors section of its website.

What presentations on canvuparatide is MBX giving at ENDO 2026 in Chicago?

MBX will present one-year open-label extension data at the 3rd Parathyroid Summit on June 12, 2026. According to MBX, full 12-week Avail Phase 2 results will be presented in an oral session at 3:00 pm CT on June 13, 2026.

Who will speak at the MBX (MBX) investor webcast on canvuparatide in June 2026?

Company management will lead the webcast, joined by Richard DiMarchi, Ph.D., and Michael T. Collins, M.D. According to MBX, DiMarchi is its scientific co-founder and Collins is a Senior Clinical Advisor at the National Institutes of Health.